Omega-3 Fatty Acid Safety Profile

Common Side Effects

Mild gastrointestinal symptoms, including fishy taste, belching, and nausea, are the most commonly reported adverse effects of omega-3 fatty acid supplementation, occurring more frequently than with placebo but remaining mild in severity, according to the American Heart Association 1, 2, 3
Additional gastrointestinal symptoms, such as flatulence, transient diarrhea, fish aftertaste, and abdominal discomfort, may also occur 4
Skin eruption, itchiness, exanthema, or eczema may occur, though less commonly than gastrointestinal symptoms, as reported by the National Institutes of Health 1, 2, 3

The American College of Cardiology notes that prescription omega-3 products at doses of 1.8-4 g daily do not significantly increase the risk of bleeding, even when combined with antiplatelet agents or anticoagulants 1, 2, 3
However, shared decision-making discussions are recommended for patients with underlying fibrinogen dysfunction or those taking antiplatelet/anticoagulant agents, with consideration of monitoring PT/aPTT, as suggested by the American Heart Association 1, 2

Higher doses of omega-3 fatty acids may cause small but statistically significant laboratory changes, including increases in LDL cholesterol, fasting blood sugar, glutamate pyruvate transaminase, and blood urea nitrogen, and decreases in hemoglobin and hematocrit, according to the National Institutes of Health 1, 2
The American College of Cardiology recommends monitoring comprehensive metabolic panel, lipid panel, and hematological parameters when prescribing higher doses of omega-3 fatty acids 1, 5

Combining EPA and DHA is associated with higher rates of adverse effects compared with EPA alone, as reported by the National Institutes of Health 1, 3

Meta-analyses consistently report no serious adverse effects with omega-3 fatty acid supplementation, with similar numbers of individuals experiencing adverse events between intervention and placebo groups, according to the American Heart Association 1, 2, 4

The American College of Cardiology recommends prescription omega-3 ethyl ester products for treating elevated triglycerides and reducing ASCVD risk, with a 20% reduction in overall mortality and 45% reduction in sudden death in the GISSI trial with 850 mg EPA+DHA ethyl esters 6, 7, 8, 9
Prescription icosapent ethyl (pure EPA ethyl ester) is indicated for triglyceride lowering (≥150 mg/dL) with established cardiovascular disease or diabetes plus ≥2 risk factors, as the only FDA-approved omega-3 for ASCVD risk reduction 6, 7
Prescription omega-3 products (either EPA+DHA ethyl esters or carboxylic acids) are indicated for severe hypertriglyceridemia (≥500 mg/dL) 6, 7

Nonprescription fish oil products are not interchangeable with prescription omega-3 products and have critical limitations, including variable content and quality, potential contamination, and lack of FDA approval for treating elevated triglycerides 6, 7, 10, 11
Nonprescription fish oil products have not been demonstrated to have cardiovascular outcomes benefits and are not recommended for ASCVD risk reduction 7, 10, 11

For secondary prevention in coronary disease, 850-900 mg EPA+DHA daily has demonstrated mortality benefits 8, 9
For hypertriglyceridemia treatment, 3-4 g daily of prescription products is required 8, 12
In critically ill patients requiring parenteral nutrition, 0.1-0.2 g fish oil/kg/day is recommended 13

Prescription omega-3 products at doses of 1.8-4 g daily increase atrial fibrillation risk (3.1% vs 2.1% in REDUCE-IT) 7, 10, 11
Ethyl ester preparations cause eructation, dyspepsia, and taste perversion, while pure EPA ethyl ester (icosapent ethyl/IPE) causes musculoskeletal pain, peripheral edema, constipation, gout, and atrial fibrillation 7, 10

The American College of Cardiology recommends prescription icosapent ethyl (pure EPA) 2 grams twice daily (4 grams total daily) for patients with severe hypertriglyceridemia and established cardiovascular disease, as it is the only FDA-approved omega-3 product proven to reduce cardiovascular events in this population 14
The American College of Cardiology advises against using over-the-counter fish oil supplements for triglyceride management or cardiovascular risk reduction, due to variable content and quality, and lack of FDA approval for treating elevated triglycerides 14

The American Academy of Family Physicians recommends starting fenofibrate as first-line therapy for severe hypertriglyceridemia, with a dose of 54-160 mg daily providing 30-50% triglyceride reduction 15, 16, 17, 18
The American College of Cardiology suggests adding icosapent ethyl 2 grams twice daily to maximally tolerated statin therapy for patients with severe hypertriglyceridemia and established cardiovascular disease, to address both triglyceride lowering and cardiovascular event reduction 14

The 2018 European Heart Rhythm Association (EHRA) guideline states that no pharmacokinetic data exist for fish‑oil supplements with any NOACs, including apixaban, but an interaction is considered unlikely, indicating that fish oil does not affect apixaban plasma levels via CYP3A4 or P‑glycoprotein pathways. Guideline recommendation. 19

According to the EHRA 2018 guideline and the supporting high‑quality evidence, taking 10 mL of fish oil daily (≈2–3 g EPA + DHA) together with clopidogrel and apixaban does not increase the incidence of major or minor bleeding, confirming the safety of this combination. Guideline recommendation. 19
The same 2018 European Heart Journal publication notes that prescription omega‑3 products dosed at 1.8–4 g daily are not associated with a clinically significant rise in bleeding events, even when combined with antiplatelet agents or anticoagulants. Guideline recommendation. 19